These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 32292557)
41. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081 [TBL] [Abstract][Full Text] [Related]
42. Syk kinase inhibitors in allergic diseases. Denyer J; Patel V Drug News Perspect; 2009 Apr; 22(3):146-50. PubMed ID: 19440557 [TBL] [Abstract][Full Text] [Related]
44. A role for spleen tyrosine kinase in renal fibrosis in the mouse obstructed kidney. Ma FY; Blease K; Nikolic-Paterson DJ Life Sci; 2016 Feb; 146():192-200. PubMed ID: 26779657 [TBL] [Abstract][Full Text] [Related]
51. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol. Kaur M; Kumari A; Bahia MS; Silakari O J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414 [TBL] [Abstract][Full Text] [Related]
52. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. Kurniawan DW; Jajoriya AK; Dhawan G; Mishra D; Argemi J; Bataller R; Storm G; Mishra DP; Prakash J; Bansal R J Control Release; 2018 Oct; 288():227-238. PubMed ID: 30219279 [TBL] [Abstract][Full Text] [Related]
53. Spleen tyrosine kinase-dependent Nrf2 activation regulates oxidative stress-induced cell death in WiL2-NS human B lymphoblasts. Park S; Jang JW; Moon EY Free Radic Res; 2018 Sep; 52(9):977-987. PubMed ID: 30203714 [TBL] [Abstract][Full Text] [Related]
54. Inhibition of Spleen Tyrosine Kinase Reduces Renal Allograft Injury in a Rat Model of Acute Antibody-Mediated Rejection in Sensitized Recipients. Ramessur Chandran S; Han Y; Tesch GH; Di Paolo J; Mulley WR; Kanellis J; Ma FY; Nikolic-Paterson DJ Transplantation; 2017 Aug; 101(8):e240-e248. PubMed ID: 28594748 [TBL] [Abstract][Full Text] [Related]
55. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509 [TBL] [Abstract][Full Text] [Related]
56. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Navara CS Curr Pharm Des; 2004; 10(15):1739-44. PubMed ID: 15180536 [TBL] [Abstract][Full Text] [Related]
57. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk. Zhao H; Caflisch A Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110 [TBL] [Abstract][Full Text] [Related]
58. Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors. Huang Y; Li Y; Dong G; Zhang W; Liu N; Sheng C Arch Pharm (Weinheim); 2018 Jun; ():. PubMed ID: 29952085 [TBL] [Abstract][Full Text] [Related]
59. Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation. Wu NL; Huang DY; Wang LF; Kannagi R; Fan YC; Lin WW J Invest Dermatol; 2016 Jan; 136(1):192-201. PubMed ID: 26763439 [TBL] [Abstract][Full Text] [Related]
60. Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response. Bian X; Wu L; Mu L; Yin X; Wei X; Zhong X; Yang Y; Wang J; Li Y; Guo Z; Ye J Fish Shellfish Immunol; 2018 Nov; 82():162-172. PubMed ID: 30114435 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]